Pregestational Diabetes (T1/T2)
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Pre-existing diabetes requires coordinated care before conception, throughout pregnancy and after birth; it is not simply an earlier diagnosis of GDM.
Assessment & interpretation
- Review glucose control, medicines, hypoglycaemia risk and retinal and renal health. Plan pregnancy with the diabetes and maternity teams.
Decisions that change management
- Give a clear plan for glucose monitoring, insulin adjustment, ketone testing during illness and urgent assessment when unwell.
- Agree delivery and intrapartum glucose plans in advance.
Follow-up & safety-netting
- Insulin requirements fall after delivery and need prompt reassessment. Discuss feeding-related hypoglycaemia prevention, follow-up and future pregnancy planning.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Suspected DKA in pregnancy requires urgent hospital/critical-care assessment even when glucose is not extremely high. Admit severe/recurrent hypoglycaemia, inability to maintain intake or maternal/fetal compromise.
When clinic, day care or home care may be suitable
- Stable type 1/type 2 diabetes needs joint obstetric/diabetes follow-up, not routine inpatient care.
Before going home
- DKA resolution includes blood ketones <0.6 mmol/L and venous pH >7.3, clinical recovery and a safe insulin transition; normal glucose alone does not establish resolution.
- Eating/drinking and glucose/electrolytes are stable; subcutaneous insulin has been given with the required overlap and specialist review. After hypoglycaemia, the cause/recurrence risk has been addressed.
Discharge medicines and treatment changes
- Never stop all insulin in type 1 diabetes. After birth reduce insulin through an individual written plan with frequent glucose review; the GDM stopping rule does not apply.
- Provide insulin, delivery devices, glucose/ketone strips and prescribed rescue treatment; teach the patient/family what to do when unwell.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
Rescue treatment when specifically prescribed with patient/family training.
- Indication: Severe insulin-associated hypoglycaemia when IV access is unavailable
- Consciousness, glucose and nausea/vomiting; replenish carbohydrate once swallowing is safe
Tests, pending results and their reviewer
- Review renal/electrolyte results after an acute event and record retinal/renal follow-up; glucose logs/CGM do not replace clinical review of recurrent lows.
Home care and counselling
- Give sick-day and hypoglycaemia instructions, out-of-hours contacts, feeding-related hypo precautions and the exact pre-birth/post-birth insulin plan.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
Before discharge after DKA/severe hypoglycaemia | Diabetes-team review, education and a booked early contact; document the precipitating cause and prevention plan. |
Within the existing joint pregnancy follow-up schedule / immediately after birth | Review glucose and doses promptly after treatment or physiological changes; do not wait for a routine 6-week check to adjust insulin. |
Return urgently
- Vomiting, ketones, dyspnoea, confusion, inability to maintain intake or severe/recurrent low glucose requires urgent hospital care.
Open the complete discharge checklist →
Treatment
① Immediate stabilization — first minutes
③ First-line treatment & drug regimens
- Pregnancy diabetes: match basal and meal insulin to the glucose pattern
- The linked NICE NG3 guidance provides pregnancy targets and treatment selection. The dose must be prescribed individually; this is an explicit dosing constraint, not a missing fixed dose.
- Record the actual basal/meal doses in the patient plan; monitor fasting, premeal/postmeal glucose or CGM
- Review patterns rather than a single high value; teach injection technique, recognition/treatment of hypoglycaemia and sick-day ketone testing
- NICE targets, if achievable without problematic hypoglycaemia: fasting <5.3 mmol/L, 1-h postmeal <7.8 or 2-h <6.4; keep glucose >4 mmol/L on insulin
④ Drug treatment detail (3 agents)
- Indication: Pregnancy DKA, including euglycaemic DKA; urgent monitored obstetric/diabetes care
- Hourly glucose and blood ketones; frequent VBG, potassium and electrolytes; target ketone fall ≥0.5 mmol/L/h
- Add 10% glucose at 125 mL/h when glucose <14 mmol/L; euglycaemic pregnancy DKA may require glucose from the start
- Continue usual long-acting basal insulin unless specialist contraindication; overlap IV insulin for 30–60 min after the appropriate subcutaneous meal dose during transition
- Indication: Impaired consciousness or unsafe swallowing; never give oral fluid to an unconscious patient
- Glucose 10 min after treatment, then serially until stable; consciousness, swallow and IV site
- Identify missed food, insulin excess, renal failure or infection; do not omit basal insulin in type 1 diabetes
- Indication: Severe insulin-associated hypoglycaemia when IV access is unavailable
- Consciousness, glucose and nausea/vomiting; replenish carbohydrate once swallowing is safe
Definitive treatment
Pre-existing insulin-treated diabetes: reduce insulin immediately after birth and monitor glucose to determine the appropriate dose. Write an individual postpartum plan; do not stop all insulin in type 1 diabetes.
Monitoring
| Parameter | Frequency |
|---|---|
Glucose review | Weekly-fortnightly clinic |
Renal | Specialist plan based on creatinine/protein and clinical changes; pregnancy eGFR is not valid |
Growth/fluid | q4 wks |
BP/proteinuria | Every visit |
Response assessment
- Acceptable A1c trend; no severe hypos; normal surveillance
Treatment failure
- Intensify regimen; endocrinology; consider admission stabilisation
Second-line treatment
- Automated delivery systems where accessible
Rescue treatment
| Potassium | Action |
|---|---|
>5.5 mmol/L | No potassium in the initial replacement fluid; recheck as treatment rapidly lowers potassium. |
3.5–5.5 mmol/L | If passing urine and renal status permits, usual replacement is premixed potassium 40 mmol/L in resuscitation fluid; account for the infusion rate and repeat levels. |
<3.5 mmol/L | Urgent senior/critical-care review for additional replacement and an insulin plan. Do not continue an unreviewed insulin prescription; concentrated potassium requires the appropriate monitored setting. |
Any potassium infusion | Never IV push potassium; use premixed/approved dilution and a labelled pump under the hospital policy. |
- Continue IV insulin until ketones <0.6 mmol/L AND venous pH >7.3 with clinical recovery; glucose correction alone does not mean DKA has resolved.
- When eating and transitioning safely, give the appropriate subcutaneous insulin and overlap IV insulin for 30–60 min. Confirm the basal regimen and prevent another missed-insulin interval.
- Abnormal fetal monitoring may improve with maternal correction; do not make automatic delivery the treatment for DKA without an obstetric indication.
Procedure / surgery
NICE: for an ultrasound-diagnosed macrosomic fetus, explain the risks and benefits of vaginal birth, induction and caesarean. Record an individual obstetric plan rather than an unsourced universal 4–4.25 kg caesarean threshold.
Escalation
- Joint diabetes-obstetric clinics
- ICU for crises
⑮ Complications & their management
DKA
Dedicated module
Congenital anomalies
Detailed scan + echo; counselling
Neonatal hypoglycaemia
Paediatric protocol
Post-treatment care
- De-escalation plan executed immediately
- Breastfeeding hypo precautions
- Contraception: POP/implant/IUD excellent
Diagnosis & assessment
- DKA (lower thresholds pregnant!)
- Severe hypoglycaemia
- Retinopathy progression
- Nephropathy/oligohydramnios
- Fetal compromise
Definition: Type 1/Type 2 diabetes predating conception.
Initial assessment
- Preconception ideal: HbA1c, retinal screen, ACR/eGFR, medication switch list (STOP ACEi/ARB/statins)
- Unscreened pregnancy confirmation: same panel urgently
- Aspirin prophylaxis + fetal echo ~19-22 wks
Investigations
| Test | Looking for |
|---|---|
HbA1c at booking; consider again in second/third trimester for risk assessment | NICE: not a routine substitute for day-to-day glucose monitoring in later pregnancy |
Retinal screening | Progression needing laser |
Renal assessment with serum creatinine and urine albumin/protein | Assess at first contact and follow the renal plan; do not use eGFR to measure renal function in pregnancy |
Principles & follow-up
Management principles
Sources (10)
2016; updates 2020–2025 (2nd ed maternal-health compendium 2025-03) · checked 2026-08-23 · verified-live
Open source ↗
WHO pages + NCBI compendium: daily IFA 30–60 mg elemental iron + 400 µg folic acid; intermittent IFA only where daily not acceptable & anaemia prevalence <20%; anaemia in ANC → 120 mg elemental iron daily until Hb normal; MMS recommended only within rigorous research contexts (supersedes 2016); ≥8 c…
25 February 2015 · updated 16 December 2020 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for gdm, pregestational-diabetes. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Subsequent diagnos…
· checked 2026-10-17 · verified-live
Open source ↗
Individualised once/twice-daily subcutaneous dosing, U-100 matching devices, NEVER-IV instruction and compatible insulin mixing order; no universal GDM starting dose invented.
· checked 2026-10-18 · verified-live
Open source ↗
Pregnancy/euglycaemic DKA cautions; soluble insulin 50 units/50 mL, 0.1 units/kg/hour, no routine bolus, glucose/ketone/electrolyte monitoring, potassium table, resolution and IV-to-SC overlap. Additional admission/discharge check 18 October 2026 (limited to the following): Resolution blood ketones …
· checked 2026-10-18 · verified-live
Open source ↗
Treat <4 mmol/L, oral carbohydrate if safe, IV glucose 20 g using 10%/20% solutions, IM glucagon 1 mg, repeat glucose checks and subsequent carbohydrate/insulin review. Additional admission/discharge check 18 October 2026 (limited to the following): Education, precipitating-cause review, ongoing glu…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.